Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinal Vein Occlusion - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2017, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 1, 8 and 2 respectively. Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Retinal Vein Occlusion - Overview Retinal Vein Occlusion - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Retinal Vein Occlusion - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Retinal Vein Occlusion - Companies Involved in Therapeutics Development Addmedica SAS Aerpio Therapeutics Inc Chengdu Kanghong Pharmaceuticals Group Co Ltd Clearside BioMedical Inc Formycon AG Kala Pharmaceuticals Inc Lupin Ltd Mabion SA Ocular Therapeutix Inc Ohr Pharmaceutical Inc ThromboGenics NV Retinal Vein Occlusion - Drug Profiles aflibercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress aflibercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress AKB-9778 - Drug Profile Product Description Mechanism Of Action R&D Progress bevacizumab SR - Drug Profile Product Description Mechanism Of Action R&D Progress conbercept - Drug Profile Product Description Mechanism Of Action R&D Progress HO-10 - Drug Profile Product Description Mechanism Of Action R&D Progress hydroxyurea - Drug Profile Product Description Mechanism Of Action R&D Progress KPI-285 - Drug Profile Product Description Mechanism Of Action R&D Progress LKA-651 - Drug Profile Product Description Mechanism Of Action R&D Progress ocriplasmin - Drug Profile Product Description Mechanism Of Action R&D Progress OTX-TKI - Drug Profile Product Description Mechanism Of Action R&D Progress Protein to Inhibit VEGF for Ophthalmology - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress squalamine lactate - Drug Profile Product Description Mechanism Of Action R&D Progress triamcinolone acetonide - Drug Profile Product Description Mechanism Of Action R&D Progress Retinal Vein Occlusion - Dormant Projects Retinal Vein Occlusion - Discontinued Products Retinal Vein Occlusion - Product Development Milestones Featured News & Press Releases Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Retinal Vein Occlusion, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2017 Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics Inc, H1 2017 Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017 Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H1 2017 Retinal Vein Occlusion - Pipeline by Formycon AG, H1 2017 Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals Inc, H1 2017 Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2017 Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2017 Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2017 Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H1 2017 Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2017 Retinal Vein Occlusion - Dormant Projects, H1 2017 Retinal Vein Occlusion - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
